LOUISVILLE, Ky. & FORT WAYNE, Ind.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM) is teaming up with eight orthopedic specialty groups in Indiana and Kentucky on an orthopedic value-based care model for Humana Medicare Advantage members undergoing total hip or knee joint replacement procedures.

Humana’s Total Joint Replacement Episode-Based Model is designed to improve quality, outcomes and cost across a person’s entire joint replacement episode of care. Humana will provide the orthopedic practices with robust data and analytics needed to better manage all aspects of their patients’ care from diagnosis to recovery. For the patient, this is expected to deliver a more coordinated care experience and to reduce complication rates and unnecessary readmissions after surgery.

In Indiana, Humana will work with Fort Wayne Orthopedics, Ortho NorthEast, Orthopaedic Associates Inc., Tri-State Orthopaedics and Unity Healthcare LLC.

In Kentucky, Humana will work with Commonwealth Orthopaedic Centers, Kentucky Bone and Joint Surgeons and Norton Orthopedic Specialists.

Humana has 30 years of experience partnering with primary care physicians in value-based arrangements. By focusing on quality and health, Humana experienced 20 percent lower costs in total in 2015 for members who were treated by doctors and other health care professionals in a value-based reimbursement model setting versus an estimation of original fee-for-service Medicare costs using the Centers for Medicare and Medicaid Services (CMS) Limited Data Set Files. Humana is now moving to apply the approach to specialties, such as orthopedics, where highly coordinated care supported by population health data has the ability to potentially improve outcomes, lower cost and deliver a better health care experience for patients.

The participating Indiana and Kentucky orthopedic groups join the 12 orthopedic groups in Ohio and Tennessee who joined Humana’s orthopedic value-based care model in 2016.

Humana’s model is similar to the State of Tennessee’s Innovation Model (SIM) Grant through CMS for Medicaid beneficiaries.

Through the new agreements, Humana’s population health capabilities, including patient data and analytics as well as chronic disease management and wellness programs, will complement the integrated care approach that each orthopedic group will employ with Humana members.

“Through our total joint replacement model, Humana is taking value-based care to the next level – from primary care to a more involved medical procedure,” said Chip Howard, Humana’s Vice President of Payment Innovation. “Humana’s approach is to provide orthopaedic surgeons the tools they need to coordinate all aspects of their patients’ diagnosis, treatment, recovery and rehabilitation to in turn improve quality, lower cost and create a better experience for our members.”

As of Dec. 31, 2016, Humana has 1.8 million individual Medicare Advantage members and 200,000 commercial members today who are cared for by 50,400 primary care providers, in more than 900 value-based relationships across 43 states and Puerto Rico. For more information, visit humana.com/accountable-care or www.humana.com/valuebasedcare.

About Humana

Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company’s strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:

• Annual reports to stockholders
• Securities and Exchange Commission filings
• Most recent investor conference presentations
• Quarterly earnings news releases and conference calls
• Calendar of events
• Corporate Governance information

More Information

Humana is a Medicare Advantage HMO, PPO and PFFS plan with a Medicare contract. Enrollment in any Humana plan depends on contract renewal. This information is not a complete description of benefits. Contact the plan for more information. Limitations, copayments and restrictions may apply. Benefits may change each year. Other providers are available in our network.

Humana Inc. and its subsidiaries (“Humana”) do not discriminate on the basis of race,color, national origin, age, disability or sex.

English: ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1-800-281-6918 (TTY: 711).

Español (Spanish): ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-281-6918 (TTY: 711).

繁體中文 (Chinese): 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1–800-281-6918 (TTY：711).

ARLINGTON, Tenn.–(BUSINESS WIRE)–MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced the launch of the EVOLUTION^®Revision Tibial System and EVOLUTION^® BioFoam^® Tibia.

“MicroPort Orthopedics continues to grow its product portfolio with a steady cadence of product launches,” said Aurelio Sahagun, President, MicroPort Orthopedics. “These product launches demonstrate our commitment to help improve patient outcomes by giving surgeons a broad array of choices that allow them to treat their patients. We are excited to bring the benefits of the Medial-Pivot design to a revision system.”

The Evolution Medial-Pivot Knee System is built on 17 years of clinical success¹ and addresses key issues that can improve satisfaction for patients undergoing total knee replacement. The EVOLUTION^® Revision Tibial System is designed to offer surgeons intra-operative flexibility to meet individual anatomic patient needs, address fixation issues caused by poor bone stock, while maintaining the proven kinematic benefits of the Medial-Pivot design. The new system was designed by expert surgeons from Europe, Asia, Canada, and the United States and features all the benefits of the EVOLUTION^® Medial-Pivot design.

In addition to its EVOLUTION^® Revision Tibial System, MicroPort Orthopedics also announced the launch of its EVOLUTION^®BioFoam^® Tibia. This launch completes the EVOLUTION^® Medial-Pivot Cementless System, which consists of the EVOLUTION^®porous femoral component and the new EVOLUTION^® BioFoam^® tibial component. This system is designed to combine the unrivaled benefits of the Medial-Pivot philosophy with the advantages of early fixation without compromising the long-term demands that are required in today’s increasingly young and more active patients.² Building on the success of the ADVANCE^® BioFoam^® Tibia, which reported survivorship of 98% at two years³, the EVOLUTION^® BioFoam^® Tibia will further enhance the product portfolio.

“I have used the MicroPort Medial-Pivot Knee System for three years,” said Dr. Brian de Beaubien, M.D., St. John’s Providence Park Hospital in Novi, MI. “The majority of my primary knees are cementless, and I do not use screws. In my experience with the ADVANCE^®and now EVOLUTION^®, BioFoam^® has excellent fixation. I have been following x-rays now for several years, and I don’t see any radiolucencies or sclerotic lines around the keel, that would suggest movement of the component. The BioFoam^® Tibia combined with the unique design of the EVOLUTION^® Medial-Pivot Knee is truly different from anything else. It is my go-to knee.”

About MicroPort Orthopedics Inc.
Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.

About MicroPort
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements
Some information contained in this press release contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Sources:
1. A long term clinical outcome of the Medial Pivot Knee Arthroplasty System Macheras, George A. et al. The Knee , Volume 24 , Issue 2 , 447 – 453.
2. Global Data, 2013.
3. Waddell et al. Early radiographic and functional outcomes of a cancellous titanium-coated tibial component for total knee arthroplasty. Musculoskelet Surg. 2015 Sept; 100: 71.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation